Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 4, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive Officer, will present at the 31^st Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013, at 12:00 p.m. Pacific Time.  The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted US and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns US and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the US For more information, please visit the Company's website at www.savient.com. 

SVNT - G

Contact:
Savient Pharmaceuticals, Inc.
John P. Hamill
Senior Vice President and Chief Financial Officer
[email protected]
(732) 418-9300

Burns McClellan
Caitlyn Murphy
[email protected]
(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.